OpenLB
Open Library of Bioscience
Advanced Search
Molecular oncology
07, 2021;15 (7): 1759-1763.

Bispecific antibodies come to the aid of cancer immunotherapy.

Ivano Amelio, Gerry Melino, Arnold J Levine
Author Information
  1. Ivano Amelio: Department of Experimental Medicine, University of Rome Tor Vergata, TOR, Rome, Italy. ORCID
  2. Gerry Melino: Department of Experimental Medicine, University of Rome Tor Vergata, TOR, Rome, Italy.
  3. Arnold J Levine: Institute for Advanced Study, Simons Center for Systems Biology, Princeton, NJ, USA.
PMID: 33942515 DOI: 10.1002/1878-0261.12977

Abstract

Three collaborative studies published by the groups of Vogelstein, Gabelli, and Zhou report the development of specially designed bispecific antibodies that may help in overcoming the limitations of current immunotherapies. The bispecific antibodies have been designed to couple cells harboring HLA-presented tumor-specific antigens from Tp53 mutant or Ras mutant with CD4 and CD8 T cells, thus facilitating immune-mediated clearance of the cancer cells.

References

  1. Biol Direct. 2020 Oct 14;15(1):18 [PMID: 33054808]
  2. J Pathol. 2021 Jul;254(4):332-343 [PMID: 33723873]
  3. Sci Immunol. 2021 Mar 1;6(57): [PMID: 33649101]
  4. Cancer Metastasis Rev. 2020 Dec;39(4):1023-1028 [PMID: 32728828]
  5. Sci Transl Med. 2021 Mar 10;13(584): [PMID: 33649188]
  6. J Clin Invest. 2019 Mar 1;129(3):1109-1114 [PMID: 30714987]
  7. Amino Acids. 2011 Jun;41(1):103-12 [PMID: 20213447]
  8. Cell Death Differ. 2019 Jan;26(2):199-212 [PMID: 30538286]
  9. Cell Cycle. 2010 Sep 15;9(18):3730-9 [PMID: 20855944]
  10. Biol Direct. 2020 Mar 4;15(1):5 [PMID: 32131875]
  11. Nat Rev Cancer. 2016 May;16(5):275-87 [PMID: 27079802]
  12. Nat Biotechnol. 2015 Oct;33(10):1079-86 [PMID: 26389576]
  13. Biol Direct. 2019 May 9;14(1):10 [PMID: 31072345]
  14. Nat Rev Mol Cell Biol. 2011 Apr;12(4):259-65 [PMID: 21427767]
  15. Cell Death Differ. 2018 Jan;25(1):144-153 [PMID: 29077094]
  16. Biol Direct. 2019 Oct 30;14(1):19 [PMID: 31666099]
  17. Cell Death Differ. 2019 Jan;26(1):115-129 [PMID: 30341424]
  18. Biochem Biophys Res Commun. 2010 Oct 29;401(4):568-73 [PMID: 20888799]
  19. Nat Rev Cancer. 2016 Aug 23;16(9):566-81 [PMID: 27550819]
  20. Biol Direct. 2019 Jul 24;14(1):11 [PMID: 31340852]
  21. Science. 2021 Mar 5;371(6533): [PMID: 33649166]
  22. Cancer Discov. 2021 May;11(5):1024-1039 [PMID: 33722796]
  23. Cell Cycle. 2014;13(20):3207-17 [PMID: 25485500]
  24. Int J Mol Sci. 2019 Dec 11;20(24): [PMID: 31835684]
  25. Cell Death Differ. 2021 Mar;28(3):843-860 [PMID: 33214663]

MeSH Term

Antibodies, Bispecific
CD8-Positive T-Lymphocytes
Humans
Immunotherapy
Neoplasms

Chemicals

Antibodies, Bispecific
Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 28

Word Cloud

Created with Highcharts 10.0.0antibodiescellsdesignedbispecificmutantcancerThreecollaborativestudiespublishedgroupsVogelsteinGabelliZhoureportdevelopmentspeciallymayhelpovercominglimitationscurrentimmunotherapiescoupleharboringHLA-presentedtumor-specificantigensTp53RasCD4CD8Tthusfacilitatingimmune-mediatedclearanceBispecificcomeaidimmunotherapy

Similar Articles

Cited By